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Down syndrome (DS) (OMIM #190685) is the most 
common chromosomal abnormality observed in 
liveborn infants, and is the most frequent genetic 
cause of mental retardation. It is a congenital disorder 
caused by the presence of a third copy of the whole, 
or a critical part, of chromosome 21 (trisomy 21). Global live-birth 
rates for DS range between 1.5 per 1  000 (1 in 660 infants)[1] and 
1.2 per 1  000 (1 in 826 infants),[2] with no predilection for race or 
socioeconomic group. Studies conducted in South Africa show a 
DS prevalence of 1.8 and 2.09 per 1 000 live births in hospital-based 
studies in urban and rural populations, respectively.[3,4]
DS is characterised by typical dysmorphic features, and is associated 
with an increased incidence of certain medical complications. The 
most common endocrine disorder associated with DS involves the 
thyroid gland.[5] Individuals with DS exhibit a wide range of thyroid 
dysfunction. The forms of hypothyroidism found in individuals 
with DS include congenital hypothyroidism (CHT), subclinical 
or ‘compensated’ hypothyroidism (SCH), transient and primary 
hypothyroidism, central hypothyroidism, thyroxin-binding globulin 
deficiency and chronic lymphocytic thyroiditis.[6] The diagnosis of 
hypothyroidism in DS is complicated by the overlap between thyroid-
associated symptoms and clinical features of the syndrome (Table 1). 
Hyperthyroidism, although rarer, also occurs more frequently in DS 
individuals than in the general population.[7]
In general, thyroid disorders have been reported to have a 
prevalence of 3 - 54% in people with DS, with the frequency of 
thyroid dysfunction increasing with age.[8] It is estimated that the 
lifetime prevalence of hypothyroidism in DS is 30 - 50%.[9] SCH is the 
most common form of thyroid dysfunction in DS, being reported in 
25 - 32% of patients.[10,11]
There are no recommended thyroid function test (TFT) reference 
ranges for children with DS, and doctors the world over have had 
to continue treating their patients with DS based on local reference 
ranges derived from studies on the general population.
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Background. While international studies show thyroid dysfunction occurs more commonly in individuals with Down syndrome (DS) than 
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practices when thyroid dysfunction was present.
Methods. A retrospective file-based study of 391 children with DS seen at the genetic clinics at three Johannesburg hospitals from 2003 to 
2008. Thyroid function test (TFT) results (thyroid-stimulating hormone and free thyroxine) and demographic details were collected for 
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controversy surrounding whether, and how, to treat SCH influenced treatment practices.
Conclusions. Thyroid dysfunction is prevalent in South African children with DS. There is an urgent need to address the laboratory 
biochemical discrepancies, and to establish guidelines for surveillance and treatment to prevent further irreversible neurological and 
physical impairment.
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It is a privilege for me to be first author of this contribution to 
Professor Jenkins’ Festschrift. Optimising the care of children with 
Down syndrome has been a priority for the Division of Human 
Genetics since Professor Jenkins started the department in the 
1970s. His legacy has continued to impact on how we view our role 
as medical geneticists who care for these children. A lot of Professor 
Jenkins’ early work focused on DS, and my work is but one attempt 
to improve the care we provide. Although he was already officially 
retired when I joined the Division, he was always willing to share 
a kind word of advice and fascinating stories about the history of 
our profession. We often chatted in the corridor outside the office I 
occupied during the last two years of my registrar training, which 
just happened to be right next to his! (Shahida Moosa)
MEDICAL GENETICS
967  December 2013, Vol. 103, No. 12 (Suppl 1)   SAMJ
In 1995, a consensus statement regarding optimal medical care for 
individuals with DS was drawn up by international experts.[12] Several 
country-specific health surveillance protocols have subsequently 
been developed. The guidelines recommend regular screening 
programmes to identify treatable causes for a variety of symptoms, 
including hypothyroidism, which might otherwise be overlooked 
in patients with DS.[13-15] As hypothyroidism impairs cognition and 
growth, and is treatable, early detection and treatment are essential in 
this already impaired population. In many parts of the world patients 
with DS have neonatal screening, as congenital hypothyroidism is one 
of the conditions included in newborn screening (NBS) programmes.
Despite these international DS thyroid screening recommendations, 
standardised biochemical treatment thresholds for DS do not exist. 
Doctors agree about the management of overt hypothyroidism 
(OHT) (increased thyroid-stimulating hormone (TSH) with low 
levels of free thyroxine (FT4)), and CHT especially carries a high risk 
of severe developmental delay if not treated promptly.[16] Conversely, 
the management of SCH is surrounded by controversy.
SCH is frequently encountered in general paediatric practice, 
but its clinical significance is widely debated. There is currently no 
consensus with regard to: (i) the morbidity and clinical significance 
of SCH; (ii) whether to investigate individuals with SCH further; 
(iii) whether patients with SCH should be treated; and (iv) if they 
are treated, at which TSH levels treatment should be instituted.
There are a few reasons for the lack of consensus surrounding the 
management of SCH. Firstly, there is a paucity of data on the natural 
history of SCH in children. The concern is that, if left untreated, SCH 
would progress to OHT. As there is also a paucity of data derived 
from patients with DS, paediatricians currently extrapolate data from 
studies on normal children and normal adults, which may not be 
applicable to children with DS. Secondly, there are no large paediatric 
randomised controlled studies comparing outcomes in patients 
with SCH who were treated with thyroxine and those left untreated. 
Again, most clinicians rely on data from adult studies, which may also 
produce conflicting recommendations.
Many of the published guidelines only support treatment with thyroid 
hormone for patients with DS where the TSH level is greater than 
10 µIU/l. Most, such as those from the UK, do not support the treatment 
of SCH when a TSH level is less than 10 µIU/l with normal FT4 values.[13]
Proponents of treatment of SCH view it as a distinct and relevant 
entity to be treated. They suggest that decreased thyroid levels may 
contribute to the poor growth and mental retardation in DS. Increased 
TSH levels reflect the sensitivity of the hypothalamic-pituitary axis to 
small decreases in circulating thyroid hormone. An FT4 level within 
the normal reference range may in fact be low for the particular 
patient, reflected as an increased TSH. Some researchers believe that 
SCH represents mild thyroid failure and should therefore be treated in 
most, if not all, cases.[17] Papi et al.[18] recommended that treatment be 
instituted in all newborns with SCH to prevent possible detrimental 
sequelae. Tüysüz and Beker[11] recommend that every infant with DS 
be treated with thyroxine until the age of 3 years. They believe that this 
will prevent OHT in children with unstable thyroid function.[11]
No standardised policy exists in South Africa with regard to 
thyroid function screening, testing or treatment in individuals with 
DS. None of the paediatric textbooks commonly used in South Africa 
mentions standard guidelines for the care of children with DS,[19,20] 
despite the fact that the American Academy of Pediatrics first issued 
its DS guidelines in 2001.[14] Lack of a standardised protocol means 
that even children born in a tertiary hospital may never have a TFT. 
Furthermore, South Africa does not have a national NBS programme. 
Congenital hypothyroidism is therefore not diagnosed in the critical, 
treatment-sensitive newborn period.
Children with DS form a substantial proportion of the patients 
seen at the three main genetic counselling (GC) clinics in the Greater 
Johannesburg area. In 2003, in line with international practice, 
clinicians in the Division of Human Genetics, National Health 
Laboratory Service (NHLS) and School of Pathology, University of the 
Witwatersrand, Johannesburg, decided to test the thyroid function of 
all children with DS seen at the GC clinics. Upon discharge from the 
clinics, all these children are issued with a referral letter recommending 
annual thyroid surveillance at their local hospitals.
This is the first study to formally audit this service and to document 
the range and prevalence of thyroid dysfunction in a cohort of South 
African children with DS. It is also a first attempt at describing the 
referral and treatment practices at two tertiary hospitals in Johannesburg.
Methods
The study was a retrospective, file-based audit of all the TFTs 
performed on children with DS at three selected academic hospitals. 
These hospitals, attached to the University of the Witwatersrand 
Medical School in the Greater Johannesburg area, were Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH), Chris Hani 
Table 1. Comparison of physical features in children with Down syndrome and hypothyroidism*
Down syndrome Hypothyroidism
Head Brachycephaly, intermediate fontanelle Normal 
Tongue Protruding Large 
Nasal bridge Underdeveloped Underdeveloped
Eyes Upslanted palpebral fissures, epicanthic folds, 
Brushfield spots (in blue eyes)
Normal 
Neck Short Short 
Heart Murmur (mainly atrioventricular canal defect) Murmur (often nonspecific)
Abdomen Umbilical hernia Umbilical hernia 
Neuromuscular Hypotonia Hypotonia 
Skin Dry Dry 
Extremities Short hands and feet, transverse palmar crease, 
clinodactyly, wide sandal gaps, hyperextensible joints
Short hands and feet
*Adapted from Coleman.[6]
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Baragwanath Academic Hospital (CHBAH) and Rahima Moosa 
Hospital (RMH). The subjects in the study were all patients with 
DS seen at one of the Division of Human Genetics’ three main GC 
clinics at these hospitals. The 6-year time period under investigation 
was from the beginning of 2003 until the end of 2008. In total, 391 
children were included in the study.
Most of the referral and treatment information was gathered from 
the GC files and the Paediatric Endocrine Clinic files from CMJAH 
and RMH. Little information was available regarding patients from 
CHBAH, as the Paediatric Endocrine Clinic files could not be accessed.
All TFTs performed on the patients with DS included in the study 
were considered valid for inclusion, unless they were performed at 
times of admission to hospital, during concurrent illness or within 
the first 48 hours after birth. Alterations in TFT results are common 
in the above situations, and can be misleading.[16] In addition, 
TFT results were excluded if the patient was on thyroid hormone 
replacement therapy at the time of testing.
For the purposes of this study, we defined the various forms of 
thyroid dysfunction as outlined in Table 2 (all using the NHLS 
paediatric reference ranges).
Data were analysed using Statistica version 10. A difference between 
the results from CHBAH and the other two hospitals combined was 
statistically proven (data not shown). The TFT data from CHBAH were 
therefore analysed independently, while the data from CMJAH and 
RMH were analysed jointly. Non-parametric variables were described 
using medians and upper and lower limits. Logistic regression analysis 
was used to verify whether any of the demographic data had a 
significant influence on the TSH results. Throughout, a p-value of 
≤0.05 was accepted as indicating statistical significance.
Ethics approval for the study was obtained from the Human 
Research Ethics Committee (Medical) of the University of the 
Witwatersrand (certificate number M090710).
Results
Demographics
Of the 391 children with DS, 48.6% were seen at CHBAH. The 
majority of these children were black (92.1%), and there were equal 
numbers of males and females. Most of the patients were tested 
between the ages of 2 and 12 months (272/317; 85.8%), with few 
tests being conducted in the neonatal period (51/327; 15.6%) and in 
children over 5 years (3/327; 0.9%).
Number of patients tested and TFTs performed
Of the 391 patients in the study, 327 (83.6%) had at least one TFT. The 
remaining 64 patients (16.4%) had no TFT result. Of those with no 
result, 82.8% (53/64) had never had a TFT, and 17.2% (11/64) either 
had a failed phlebotomy attempt or insufficient blood submitted for 
analysis. Numbers of tests, by individual hospital, are shown in Table 3. 
From these 327 patients, a total of 536 TFT results were collected and 
516 were suitable for further analysis. More than half of all TFTs were 
requested by the doctors at the GC clinics (54.0%), followed by the 
general paediatricians (35.5%) and other paediatric specialists (10.5%).
Thyroid dysfunction spectrum
As 516 results were collected from 327 patients, several patients clearly 
had more than one TFT. For clarity, the results are presented in terms 
of number of abnormal TFT results, and then number of actual affected 
patients. When patients were found to have more than one result, the 
assignment of thyroid function category relied on the initial test result.
A wide spectrum of thyroid dysfunction was represented in this 
cohort, with the noticeable exception of hyperthyroidism. Results 
mostly reflected a euthyroid state (295/516; 57.2%), but a large 
proportion (148/516; 28.7%) fell into the SCH category. Table 4 
summarises the results in the different thyroid function categories. 
Although only 51 children had a TFT during the newborn period, it 
is notable that 23.5% had CHT.
Referral, management and follow-up
At the Paediatric Endocrine Clinic at CMJAH, almost all patients with 
DS are placed on thyroid hormone supplementation, unless they are 
overtly hyperthyroid. At the Paediatric Endocrine Clinic at RMH, only 
patients with a TSH >10  µIU/l are treated, unless there is significant 
clinical evidence to suggest hypothyroidism at lower TSH levels. In this 
cohort, all patients with OHT and TSH levels exceeding 10 µIU/l referred 
to the endocrine clinics at RMH and CMJAH were on treatment. There 
were 39 patients with SCH and a TSH level >10 µIU/l, 12 (30.8%) of 
whom were reportedly on thyroxine replacement treatment.
Non-referral of patients with OHT and CHT to the endocrine 
clinics ranged from a rate of 26.7% at CMJAH to 43.2% at CHBAH. 
Rates of non-referral for those with SCH ranged from 47.8% at 
CHBAH to 57.1% at RMH. Of the 12 neonates with CHT, at least a 
quarter were not referred for treatment during the neonatal period. 
The patients with further abnormal results (Table 4) were not referred 
for further assessment.
Few patients (11/327; 3.4%) had yearly TFTs. Regular annual tests 
were performed by the doctors in the GC clinics (6/11; 54.5%), at the 
endocrine or developmental clinic (3/11; 27.3%), or at a peripheral 
hospital (2/11; 18.2%). Some patients (10/327; 3.1%) had ad hoc TFTs 
performed, presumably when they accessed healthcare.
Differences observed between the hospitals
A difference between the medians of the TFTs from the three 
hospitals was anticipated, because they use different machines for TFT 
Table 3. Patients tested
TST result, n (%)
Hospital Available None/not available
CHBAH (N=190) 165 (42.2) 25 (6.4)
CMJAH (N=131) 106 (27.1) 25 (6.4)
RMH (N=70) 56 (14.3) 14 (3.6)
Total (N=391) 327 (83.6) 64 (16.4)
TFT = thyroid function test; CHBH = Chris Hani Baragwanath Academic Hospital;  
CMJAH = Charlotte Maxeke Johannesburg Academic Hospital; RMH = Rahima Moosa Hospital.
Table 2. Operational definitions
Congenital hypothyroidism (CHT) Any patient with a high TSH level demonstrated within the newborn period (first 2 - 28 days of life)
Subclinical hypothyroidism (SCH) A high TSH level in the presence of a normal FT4 level
Overt hypothyroidism (OHT) A high TSH level and a correspondingly low FT4 level
Hyperthyroidism A low TSH level and a high FT4 level
TSH = thyroid-stimulating hormone; FT4 = free thryoxine.
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analysis. There was no difference between the hospitals with regard 
to other variables (age ranges, race stratification, gender stratification 
or chromosome results). Analysis of variance confirmed a statistical 
difference between CHBAH and the other two hospitals (p<0.05), but 
not between CMJAH and RMH (p>0.05). A single patient was tested 
at CHBAH and CMJAH, a week apart. Using the result from CHBAH, 
the child would have been classified as having SCH, but the repeat test 
at CMJAH was within normal limits for his age.
Discussion
This study highlights several important issues regarding the 
diagnosis, referral and management of children with DS and thyroid 
dysfunction.
Given the resource constraints placed on the healthcare system 
by the burden of diseases such as HIV and tuberculosis, an overall 
thyroid testing rate of 83.6% in this cohort is remarkable. The cohort 
displayed a similar spectrum of thyroid dysfunction to international 
cohorts, with SCH being the most common problem encountered. 
However, no children were found to be hyperthyroid in this study, 
probably because very few tests were conducted in older children.
Although most of the children in the study were tested, there was 
a less structured approach to referral of those with an abnormal 
TFT result. Lack of referral of these patients at all the tertiary 
hospitals resulted in patients remaining without adequate endocrine 
assessment and treatment. This included patients with a clear 
diagnosis of SCH, CHT or OHT. Additionally, patients with results 
suggestive of central hypothyroidism, or an inadequate response from 
the hypothalamic-pituitary-thyroid axis, went uninvestigated.
Failed phlebotomy or insufficient blood submitted for analysis 
resulted in 11 children not having a TFT result. All TFTs are 
performed on venous blood, usually obtained from a peripheral vein. 
Too little blood may be obtained when phlebotomy in children with 
DS is difficult because of their short necks and tendency to become 
overweight, and an expert phlebotomist is needed to perform the 
venepuncture in such cases. Alternatives to classic phlebotomy 
such as finger/heel prick tests are viable, especially for detecting 
hypothyroidism.[21,22]
The lack of referral can partly be explained by the lack of a 
standardised guideline outlining the process for active thyroid 
surveillance of children with DS. To benefit the patient, testing, 
as the first step in the surveillance protocol, must be followed by 
appropriate referral and treatment.
Owing to lack of specific guidelines, clinicians are left to judge 
clinically when to institute thyroid replacement treatment, which, 
based on the DS phenotype, can prove problematic. The controversy 
surrounding SCH seemed to extend to the present study cohort as 
well. While the paediatric endocrinologists at the different hospitals 
agree that SCH is a true reflection of patients’ thyroid status, they 
differ with regard to its appropriate management. Nevertheless, the 
two different approaches can each be justified.
Moreover, doctors are faced with the challenge of trying to 
interpret results from black African children, using reference ranges 
derived from a different ethnic population. The situation is even 
more complicated when those black African children also have DS.
The statistically significant difference observed between results 
from the CHBAH laboratory and the other hospitals also highlights 
the possibility that there may be significant inter-laboratory 
differences, adding to the difficulty of interpretation of TFT results.
Conclusion
Left untreated, hypothyroidism causes irreversible mental and 
physical handicaps. Early detection and treatment is therefore 
desirable, particularly in children who already have a predisposition 
to learning disabilities and growth impairment.
Optimising the care for children with DS should be prioritised. It is 
vital that a standardised, national surveillance protocol be established 
to specifically address the health needs of children with DS in South 
Africa, while taking into account the country’s limited resources. The 
guidelines would need to include standardised nationwide protocols 
for thyroid surveillance. Ideally this would include TFT testing for all 
newborns with DS, annual thyroid surveillance of all children with 
DS, active and appropriate referral for monitoring and treatment, less 
invasive testing techniques, and the facilities to have these tests and 
treatment as close to home as possible. The guidelines would preferably 
be implemented in the primary or secondary hospital systems.
However, the immediate implementation of such guidelines is 
hampered by several issues. The first is the discrepancy between the 
laboratories noted in this study. Urgent studies are needed to delineate 
the exact causes of the differences. Alternative testing methods, such as 
heel prick tests, should be optimised as a matter of urgency. Whether 
establishing DS-specific TFT reference ranges would prove beneficial in 
the South African healthcare setting also requires further consideration.
Secondly, the absence of an NBS policy in South Africa means that 
children with DS who have CHT are not being diagnosed during the 
Table 4. Summary of abnormal thyroid function test results and number of affected patients
n/N (%)
Thyroid function category Abnormal results Affected patients
Subclinical hypothyroidism
TSH >10 µIU/l  
148/516* (28.7)
46/148 (31.1)
99/327† (30.3)
39/99 (39.4)
Congenital hypothyroidism
TSH >10 µIU/l
16/62 (25.8) results from newborns 
12/16 (75)
12/51 (23.5) children tested
Overt hypothyroidism
TSH >10 µIU/l
14/516 (2.7)
8/14 (57.1)
14/327 (4.3)
8/14 (57.1)
Hyperthyroidism 0/516 (0) 0/327 (0)
Increased FT4 with normal TSH 14/516 (2.7) 14/327 (4.3)
Isolated increased FT4 19/516 (3.7) 19/327 (5.8)
Increased TSH and FT4 12/516 (2.3) 12/327 (3.7)
TSH = thyroid-stimulating hormone; FT4 = free thyroxine.
*Total number of results.†Total number of patients tested.
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neonatal period, which is the ideal time to institute treatment. Instituting 
a national NBS to test for thyroid dysfunction will benefit not only 
newborns with DS, but the general population of neonates as well.
Without the abovementioned prerequisites, national DS surveil-
lance guidelines would be of little practical value. It is hoped that the 
results of this study will increase awareness of the current challenges 
and form the basis for discussion around the management and care of 
children with DS in South Africa, finally leading to more structured 
protocols regarding health screening and treatment of complications 
associated with DS.
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